Document Detail

Expression of FOXP3, CD68, and CD20 at Diagnosis in the Microenvironment of Classical Hodgkin Lymphoma Is Predictive of Outcome.
MedLine Citation:
PMID:  23045593     Owner:  NLM     Status:  Publisher    
PURPOSEThe immune microenvironment is key to the pathophysiology of classical Hodgkin lymphoma (CHL). Twenty percent of patients experience failure of their initial treatment, and others receive excessively toxic treatment. Prognostic scores and biomarkers have yet to influence outcomes significantly. Previous biomarker studies have been limited by the extent of tissue analyzed, statistical inconsistencies, and failure to validate findings. We aimed to overcome these limitations by validating recently identified microenvironment biomarkers (CD68, FOXP3, and CD20) in a new patient cohort with a greater extent of tissue and by using rigorous statistical methodology. PATIENTS AND METHODSDiagnostic tissue from 122 patients with CHL was microarrayed and stained, and positive cells were counted across 10 to 20 high-powered fields per patient by using an automated system. Two statistical analyses were performed: a categorical analysis with test/validation set-defined cut points and Kaplan-Meier estimated outcome measures of 5-year overall survival (OS), disease-specific survival (DSS), and freedom from first-line treatment failure (FFTF) and an independent multivariate analysis of absolute uncategorized counts. RESULTS: FFTF 93%, 62%, and 47% (P < .001), DSS 93%, 82%, and 63% (P = .03), and OS 93%, 82%, and 59% (P = .002). CONCLUSIONWe have independently validated CD68, FOXP3, and CD20 as prognostic biomarkers in CHL, and we demonstrate, to the best of our knowledge for the first time, that combining FOXP3 and CD68 may further improve prognostic stratification.
Paul Greaves; Andrew Clear; Rita Coutinho; Andrew Wilson; Janet Matthews; Andrew Owen; Milensu Shanyinde; T Andrew Lister; Maria Calaminici; John G Gribben
Related Documents :
7199593 - Symptomatological classification in the development of stroke in stroke-prone spontaneo...
24379223 - Dynamic 18f-fet pet in newly diagnosed astrocytic low-grade glioma identifies high-risk...
11786113 - Vascular access use in europe and the united states: results from the dopps.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-8
Journal Detail:
Title:  Journal of clinical oncology : official journal of the American Society of Clinical Oncology     Volume:  -     ISSN:  1527-7755     ISO Abbreviation:  J. Clin. Oncol.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8309333     Medline TA:  J Clin Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Paul Greaves, Andrew Clear, Rita Coutinho, Andrew Wilson, Janet Matthews, Andrew Owen, T. Andrew Lister, Maria Calaminici, and John G. Gribben, Barts Cancer Institute, Queen Mary University of London, London; and Milensu Shanyinde, Centre for Statistics in Medicine, University of Oxford, Wolfson College, Oxford, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter stu...
Next Document:  Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-ce...